Alopecia areata often starts in childhood, carries a heavy psychosocial burden, and until recently had almost nothing to offer a child with extensive disease. Janus kinase inhibitors changed that clinically well before they changed it on the label. A clinical review sets out where the evidence actually stands and how to use these drugs responsibly in children.

The regulatory position is narrow and specific: ritlecitinib is the only Janus kinase inhibitor with United States Food and Drug Administration approval for paediatric alopecia areata, and only from age 12. Everything else — abrocitinib, baricitinib, deuruxolitinib, ruxolitinib, tofacitinib, upadacitinib — is off-label in children, with meaningful regrowth reported across case series and clinical experience and generally favourable safety. The review also flags who may do best: children with concomitant atopic or autoimmune disease, and those with raised immunoglobulin E or eosinophilia. Early-onset and severe disease are grounds for considering systemic therapy sooner rather than later.

That combination — real benefit, thin formal evidence, mostly off-label — is what makes this a consent and governance issue as much as a prescribing one. Outcome reporting across the source studies was heterogeneous, so the effect size in children is not firmly established. The practical answer is to treat, but to treat with the documentation, monitoring and explicit off-label consent that the evidence base requires. In India the relevant regulatory position is CDSCO's rather than the FDA's, and paediatric approvals here should be checked directly rather than assumed from the American label.

Document off-label status and the discussion of it in the notes before the first prescription.
Consider a Janus kinase inhibitor earlier in early-onset or extensive paediatric disease rather than after everything else has failed.
Screen for atopic and autoimmune comorbidity, and check immunoglobulin E and eosinophil count — they may identify better responders.
Confirm age indication and paediatric approval with CDSCO for Indian practice; the FDA label does not settle it here.
Agree a stopping rule and a review date at the start, with baseline severity scoring and photographs.

Why it matters

The gap between what these drugs do in children and what they are licensed to do in children is now wide enough that the prescribing decision has to be made deliberately rather than by default.

Don't overread it

This is a clinical review synthesising heterogeneous case series and experience, not a trial — it supports careful use, not a claim about how well these drugs work in children.